Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
BHVN
Biohaven Ltd.
BHVN's Kv7 ion channel modulation platform (BHV-7000) and TRPM3 antagonist (BHV-2100) position the company in Ion Channel Modulators, a key neuroscience/pain modality.
|
$1.39B |
$13.13
+10.15%
|
|
PHVS
Pharvaris N.V.
Pharvaris' lead program deucrictibant is an oral small-molecule therapeutic targeting Bradykinin B2 receptor for HAE/AAE, fitting the 'Oral Small Molecule Therapeutics' category.
|
$1.37B |
$25.14
-1.99%
|
|
TNDM
Tandem Diabetes Care, Inc.
Tandem Diabetes Care manufactures insulin pumps (medical devices) and biometric sensing data integration, a core medical device product line.
|
$1.36B |
$20.18
-4.25%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX's lead programs are peptide-based therapeutics delivered via a proprietary long-acting Precision Endocrine Peptide (PEP™) platform, i.e., Peptide Therapeutics.
|
$1.36B |
$40.56
-0.86%
|
|
NTLA
Intellia Therapeutics, Inc.
Direct focus on CRISPR-based in vivo gene therapies (NTLA-2002 and nex-z) and a delivery platform, i.e., core gene-therapy biotech business.
|
$1.34B |
$12.48
+5.18%
|
|
ASTH
Astrana Health, Inc.
Astrana operates outpatient clinics and ambulatory surgical centers, i.e., care delivery services.
|
$1.32B |
$23.86
+6.21%
|
|
PGEN
Precigen, Inc.
Direct platform and lead asset are gene therapy products, making Biotech - Gene Therapy a core tag.
|
$1.31B |
$4.39
+6.16%
|
|
USPH
U.S. Physical Therapy, Inc.
Directly operates outpatient physical therapy clinics and ambulatory care services.
|
$1.31B |
$86.11
-1.81%
|
|
CLOV
Clover Health Investments, Corp.
Clover Health operates Medicare Advantage plans and provides health insurance benefits.
|
$1.30B |
$2.54
-2.86%
|
|
NVAX
Novavax, Inc.
Novavax develops, manufactures, and commercializes vaccines (e.g., Nuvaxovid), placing it squarely in the vaccines product category.
|
$1.30B |
$8.00
+2.76%
|
|
IRMD
IRadimed Corporation
IRADIMED monetizes proprietary disposables and consumables for its infusion pumps and monitoring devices, generating recurring revenue.
|
$1.30B |
$102.20
-0.36%
|
|
CNMD
CONMED Corporation
A large share of revenues comes from single-use disposable medical device products, i.e., consumables.
|
$1.29B |
$41.56
-2.33%
|
|
ANAB
AnaptysBio, Inc.
Lead programs are monoclonal antibody therapeutics (antibodies such as rosnilimab, ANB033, ANB101).
|
$1.28B |
$45.65
-1.43%
|
|
TRVI
Trevi Therapeutics, Inc.
Trevi Therapeutics develops Haduvio, an oral small molecule therapeutic (nalbuphine ER) for chronic cough.
|
$1.28B |
$10.47
-2.65%
|
|
AMLX
Amylyx Pharmaceuticals, Inc.
AMX0035 is an oral fixed-dose combination therapy, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$1.28B |
$14.31
+5.88%
|
|
RLAY
Relay Therapeutics, Inc.
Directly develops oncology therapies (lead asset RLY-2608) and precision medicine leveraging its platform.
|
$1.27B |
$7.34
-3.74%
|
|
PHAR
Pharming Group N.V.
Core rare-disease therapeutic developer focused on RUCONEST and an expanding rare-disease pipeline.
|
$1.25B |
$18.39
+1.27%
|
|
QURE
uniQure N.V.
Core business is development and commercialization of gene therapies (e.g., AMT-130) using viral vectors, i.e., direct gene therapy products.
|
$1.25B |
$22.85
+3.96%
|
|
TSHA
Taysha Gene Therapies, Inc.
TSHA-102 is an AAV9-based gene therapy product directly developed by Taysha for Rett syndrome.
|
$1.24B |
$4.55
-7.14%
|
|
SDGR
Schrödinger, Inc.
The company operates a proprietary drug discovery pipeline with programs in oncology, aligning with Biotech - Oncology.
|
$1.24B |
$16.79
-3.89%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
ABCL
AbCellera Biologics Inc.
AbCellera's primary product is its antibody discovery platform.
|
$1.23B |
$4.12
-1.56%
|
|
ARDT
Ardent Health Partners, LLC
Ardent operates hospitals delivering acute inpatient and related hospital services.
|
$1.23B |
$8.60
-3.37%
|
|
INVA
Innoviva, Inc.
Zoliflodacin is an oral small-molecule therapeutic in Innoviva's pipeline, representing the IST focus on oral antibiotics.
|
$1.23B |
$19.43
-1.67%
|
|
XERS
Xeris Biopharma Holdings, Inc.
Xeris's XeriSol and XeriJect drug-delivery platforms enable stable, ready-to-use injectable formulations, a core differentiator.
|
$1.21B |
$7.53
+1.62%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$1.21B |
$26.08
+0.31%
|
|
IMTX
Immatics N.V.
Core product platform: TCR-engineered cell therapies (ACT) for solid tumors.
|
$1.19B |
$9.84
-0.81%
|
|
NNE
Nano Nuclear Energy Inc
Company engages in laboratory testing/advisory services related to nuclear tech development and regulatory readiness.
|
$1.18B |
$26.58
-6.70%
|
|
ORIC
ORIC Pharmaceuticals, Inc.
ORIC develops oncology therapies (e.g., ORIC-944, ORIC-114, ORIC-533) targeting cancer resistance, placing it in Biotech - Oncology.
|
$1.18B |
$12.12
+5.16%
|
|
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Core product is Cardiology devices: wearable defibrillator (ASSURE WCD) and related cardiac therapy platform.
|
$1.18B |
$22.87
-0.48%
|
|
BLFS
BioLife Solutions, Inc.
Sells consumables such as hPL, CellSeal vials, and CryoCase used within CGT workflows.
|
$1.17B |
$24.41
-0.27%
|
|
SEPN
Septerna, Inc.
Septerna is focused on discovering and developing oral small molecule therapeutics targeting GPCRs (e.g., preclinical metabolic programs and GPCR targets under Novo Nordisk collaboration), which maps to the 'Oral Small Molecule Therapeutics' investable theme.
|
$1.16B |
$26.05
-4.84%
|
|
CSTL
Castle Biosciences, Inc.
Castle Biosciences provides oncology biomarker diagnostics (DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher BE) using gene expression profiling and spatial omics, aligning with Biotech - Oncology.
|
$1.16B |
$39.98
-1.88%
|
Showing page 13 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
